「REDUCE」－リスクの高い男性における前立腺がんの発症率を低下させるための臨床研究

基本情報

NCT ID

NCT00056407

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

8,231

治験依頼者名

GlaxoSmithKline

概要

This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.

対象疾患

介入

依頼者（Sponsor）